The 'rule of three' for fragment-based drug discovery: where are we now? - PubMed (original) (raw)

The 'rule of three' for fragment-based drug discovery: where are we now?

Harren Jhoti et al. Nat Rev Drug Discov. 2013 Aug.

No abstract available

PubMed Disclaimer

Similar articles

• What is the future for fragment-based drug discovery?
  Keserű GM, Hann MM. Keserű GM, et al. Future Med Chem. 2017 Sep;9(13):1457-1460. doi: 10.4155/fmc-2017-0106. Epub 2017 Aug 10. Future Med Chem. 2017. PMID: 28795595 No abstract available.
• Fragments: where are we now?
  Osborne J, Panova S, Rapti M, Urushima T, Jhoti H. Osborne J, et al. Biochem Soc Trans. 2020 Feb 28;48(1):271-280. doi: 10.1042/BST20190694. Biochem Soc Trans. 2020. PMID: 31985743 Review.
• From fragment screening to potent binders: strategies for fragment-to-lead evolution.
  Eitner K, Koch U. Eitner K, et al. Mini Rev Med Chem. 2009 Jul;9(8):956-61. doi: 10.2174/138955709788681645. Mini Rev Med Chem. 2009. PMID: 19601891 Review.
• Ligand specificity, privileged substructures and protein druggability from fragment-based screening.
  Barelier S, Krimm I. Barelier S, et al. Curr Opin Chem Biol. 2011 Aug;15(4):469-74. doi: 10.1016/j.cbpa.2011.02.020. Epub 2011 Mar 14. Curr Opin Chem Biol. 2011. PMID: 21411360 Review.
• Benefits of Strategic Small-Scale Targeted Screening.
  Sharlow ER. Sharlow ER. Assay Drug Dev Technol. 2016 Aug;14(6):329-32. doi: 10.1089/adt.2016.734. Epub 2016 Jun 24. Assay Drug Dev Technol. 2016. PMID: 27341343 Review.

Cited by

• Fragment-based design of SARS-CoV-2 Mpro inhibitors.
  Teli DM, Patel B, Chhabria MT. Teli DM, et al. Struct Chem. 2022;33(6):2155-2168. doi: 10.1007/s11224-022-02031-w. Epub 2022 Aug 24. Struct Chem. 2022. PMID: 36035593 Free PMC article.
• Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.
  Scott DE, Bayly AR, Abell C, Skidmore J. Scott DE, et al. Nat Rev Drug Discov. 2016 Aug;15(8):533-50. doi: 10.1038/nrd.2016.29. Epub 2016 Apr 11. Nat Rev Drug Discov. 2016. PMID: 27050677 Review.
• Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.
  Scheufler C, Möbitz H, Gaul C, Ragot C, Be C, Fernández C, Beyer KS, Tiedt R, Stauffer F. Scheufler C, et al. ACS Med Chem Lett. 2016 Jun 6;7(8):730-4. doi: 10.1021/acsmedchemlett.6b00168. eCollection 2016 Aug 11. ACS Med Chem Lett. 2016. PMID: 27563394 Free PMC article.
• Biophysics in drug discovery: impact, challenges and opportunities.
  Renaud JP, Chung CW, Danielson UH, Egner U, Hennig M, Hubbard RE, Nar H. Renaud JP, et al. Nat Rev Drug Discov. 2016 Oct;15(10):679-98. doi: 10.1038/nrd.2016.123. Epub 2016 Aug 12. Nat Rev Drug Discov. 2016. PMID: 27516170 Review.
• Mapping oncogenic protein interactions for precision medicine.
  Sharifi Tabar M, Francis H, Yeo D, Bailey CG, Rasko JEJ. Sharifi Tabar M, et al. Int J Cancer. 2022 Jul 1;151(1):7-19. doi: 10.1002/ijc.33954. Epub 2022 Feb 14. Int J Cancer. 2022. PMID: 35113472 Free PMC article. Review.

References

1. 1. Nat Chem. 2013 Jan;5(1):21-8 - PubMed
2. 1. Nature. 2007 Dec 13;450(7172):1001-9 - PubMed
3. 1. Nat Rev Drug Discov. 2013 Jan;12(1):5-7 - PubMed
4. 1. J Med Chem. 2011 Nov 24;54(22):7784-96 - PubMed
5. 1. Nat Rev Drug Discov. 2011 Sep 30;10(10):749-65 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • H1 Connect
  • scite Smart Citations